Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.82
-4.7%
$0.51
$0.17
$2.93
$2.61M-0.07161,471 shs1,896 shs
iBio, Inc. stock logo
IBIO
iBio
$0.93
-3.1%
$0.75
$0.56
$6.89
$18.93M0.861.49 million shs472,960 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.215,550 shsN/A
PainReform Ltd. stock logo
PRFX
PainReform
$1.42
-1.4%
$1.47
$1.25
$16.63
$2.90M0.588.83 million shs112,535 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-4.65%+11.56%+42.96%+293.85%-71.72%
iBio, Inc. stock logo
IBIO
iBio
-3.07%+11.80%+28.05%+0.58%-50.87%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%-50.00%0.00%0.00%
PainReform Ltd. stock logo
PRFX
PainReform
-1.39%0.00%-2.07%-23.66%-62.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.82
-4.7%
$0.51
$0.17
$2.93
$2.61M-0.07161,471 shs1,896 shs
iBio, Inc. stock logo
IBIO
iBio
$0.93
-3.1%
$0.75
$0.56
$6.89
$18.93M0.861.49 million shs472,960 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.215,550 shsN/A
PainReform Ltd. stock logo
PRFX
PainReform
$1.42
-1.4%
$1.47
$1.25
$16.63
$2.90M0.588.83 million shs112,535 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-4.65%+11.56%+42.96%+293.85%-71.72%
iBio, Inc. stock logo
IBIO
iBio
-3.07%+11.80%+28.05%+0.58%-50.87%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%-50.00%0.00%0.00%
PainReform Ltd. stock logo
PRFX
PainReform
-1.39%0.00%-2.07%-23.66%-62.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
3.00
Buy$5.00435.62% Upside
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest NPHC, ATXI, IBIO, and PRFX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
iBio, Inc. stock logo
IBIO
iBio
$400K45.87N/AN/A$1.41 per share0.66
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$440K0.00N/A0.08N/ANaN
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/A$2.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$0.950.04N/AN/A-471.57%-296.50%11/12/2025 (Estimated)
iBio, Inc. stock logo
IBIO
iBio
-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$8.18MN/A0.00N/AN/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
-$14.59M-$147.33N/AN/AN/AN/AN/A9/18/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
iBio, Inc. stock logo
IBIO
iBio
0.05
1.76
1.76
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/A
1.81
1.81

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
iBio, Inc. stock logo
IBIO
iBio
7.90%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
PainReform Ltd. stock logo
PRFX
PainReform
37.28%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
iBio, Inc. stock logo
IBIO
iBio
0.58%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
iBio, Inc. stock logo
IBIO
iBio
10019.66 million9.82 millionN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
PainReform Ltd. stock logo
PRFX
PainReform
42.01 million1.32 millionNot Optionable

Recent News About These Companies

Nvidia enrollment sends this stock soaring 130%
PainReform/DeepSolar Accepted into NVIDIA Connect Program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.82 -0.04 (-4.65%)
As of 09/12/2025 03:44 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

iBio stock logo

iBio NYSE:IBIO

$0.93 -0.03 (-3.07%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$0.92 -0.01 (-0.91%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

PainReform stock logo

PainReform NASDAQ:PRFX

$1.42 -0.02 (-1.39%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.40 -0.02 (-1.34%)
As of 09/12/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.